当前位置: X-MOL 学术J. Clin. Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Another Victory for Immune Checkpoint Blockade in Melanoma: Adjuvant Ipilimumab Over Interferon.
Journal of Clinical Oncology ( IF 45.3 ) Pub Date : 2019-12-27 , DOI: 10.1200/jco.19.02988
Allison Betof Warner 1, 2 , Michael A Postow 1, 2
Affiliation  

Before the immune checkpoint blockade era, patients with surgically resected, high-risk melanoma faced difficult prognoses. Recurrence rates were high, overall survival (OS) was poor, and treatment options were limited to interferon alfa-2b. Interferon offered patients improvement in recurrence-free survival (RFS), but its use was limited by significant adverse effects and controversial impact on OS.

中文翻译:

黑色素瘤免疫检查点封锁的另一项胜利:依匹莫单抗在干扰素上的辅助治疗。

在免疫检查点封锁时代之前,手术切除的高危黑色素瘤患者面临困难的预后。复发率高,总生存期(OS)差,治疗选择仅限于干扰素α-2b。干扰素可为患者提供无复发生存率(RFS)的改善,但其使用受到严重的不良反应和对OS的争议影响而受到限制。
更新日期:2020-02-18
down
wechat
bug